Yahoo Finance3d
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
In addition, Merck will pay up to $1.77 billion in milestone payments as well as royalties on the drug’s future sales ... for cardiovascular disease like heart attack and stroke.
ConsumerAffairs8d
FDA greenlights new drug to treat a serious type of heart disease
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal
Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Newsable Asianet News on MSN3d
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
Merck & Co., Inc. (MRK) said on Tuesday that it has entered into an exclusive license agreement with China-based Jiangsu ...
MT Newswires on MSN3d
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate
Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday that ...